Study DMID 09-066 – Phase I, dmLT adjuvant safety and immunogenicity
The dmLT adjuvant was studied in a dose-escalation clinical phase-I trial evaluating safety and immunogenicity of a single oral administration. The dmLT was safe and well tolerated by the 36 study participants. The study was conducted under an US IND.
Studies
- All studies
-
Study OEV-128 – Phase IIB Study in children 6-18 months in The Gambia
-
Study OEV-124 – Phase I, Age-descending study in Zambia
-
Study OEV-123 – Phase IIb Safety, diagnostic methodology evaluation and estimated vaccine efficacy in travellers to Benin
-
Study OEV-122 – Phase I/II, Age descending safety and immunogenicity trial in Bangladesh (age ≥6 mo)
-
Study OEV-121A – Phase I, Booster dose memory study
-
Study OEV-121 – Phase I, Safety and immunogenicity of vaccine
-
Study OEV-120 – Phase I, Safety and immunogenicity of a prototype vaccine
-
Study DMID 09-066 – Phase I, dmLT adjuvant safety and immunogenicity
-